{"name":"Zenas BioPharma","slug":"zenas","ticker":"ZBIO","exchange":"NASDAQ","domain":"zenasbio.com","description":"Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.","hq":"Waltham, MA","founded":0,"employees":"167","ceo":"Neil Kahrim","sector":"Autoimmune / Immunology","stockPrice":20.86,"stockChange":-1.62,"stockChangePercent":-7.21,"marketCap":"$1.3B","metrics":{"revenue":10000000,"revenueGrowth":-100,"grossMargin":100,"rdSpend":168063000,"netIncome":-377737000,"cash":343192000,"dividendYield":0,"peRatio":-4.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ZEN-271 patent cliff ($0.0B at risk)","drug":"ZEN-271","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"ZEN-3694 patent cliff ($0.0B at risk)","drug":"ZEN-3694","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Zenas BioPharma Announces FDA Fast Track Designation for ZEN-271","summary":"Zenas BioPharma announced that the FDA has granted Fast Track designation to ZEN-271, an investigational treatment for autoimmune hepatitis.","drugName":"ZEN-271","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Zenas BioPharma Reports Third Quarter 2023 Financial Results","summary":"Zenas BioPharma reported its third quarter 2023 financial results, with a net loss of $23.6 million and a cash balance of $143.8 million.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOUVBVOV9LYlZwT1RiQWYyazA2amNmUTZvdXkxNXdtd2h1NmNrdzRDVXZBR09XUHdObG5hVWFHRUVlaXFZdVFXbTZuUVEta3ZLRFJzSnRrUktVSlhRekZBU0JEQkRkUlVnYUF0OENMYm1DS3MzUXNFaDgtV3JtdlJZdE8xUllmbGVOeXV1NVhrVGMwa0ExaWNsSVRSYXcyWTdVSDlnampkUERWdzE2MmVrMEJKMUpGV3M0bEdVeU84QVVmUQ?oc=5","date":"2026-03-21","type":"pipeline","source":"The Motley Fool","summary":"ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch - The Motley Fool","headline":"ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOeW1wS3AzMkF1M2pyTTd0bWo4Tk1EY3dxR0hlcWFwM1pBc19HUC1OMFVJYTd1OXktZ0s5UURBWVJJVWdUa1V1RUpPbjBxRmxZUXZZTFhlWkdOdk1XYWk5RWtLRUFMa3lZbk1hWmhuZ2hXcS1Lem5zZFFwZHA5UFdPa1N2MkpkRG43eHMwY1gyUnZQTk1vMTBDT1B5OW1Hb0ZrUnJYVER2MzhzUTd5Y19GTG5SVmVFdU1xYktN?oc=5","date":"2026-01-16","type":"pipeline","source":"Stock Titan","summary":"New hire at Zenas BioPharma receives option on 100,000 company shares - Stock Titan","headline":"New hire at Zenas BioPharma receives option on 100,000 company shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNNk8xWkdJb2dDUm5qMEp1TENKZXRDNy04cUlfTnlxeWhSd21qR3NLNnRhQjhDMC03X0thWm9ZakxxM0VNaHZaV0l5MVZKSUFPQkhTWC1uVHZaeGZnaVQ4UHpKSV9acmJkcHExQlE0VWhQSlIzSFZmYjZHNmY3SmpYOU1jTW1RRXBLcjBIZHdLWmc0OHJsWTRUZDIxYXZKTnVBYVREOFZSdjZnOTdqdHhnTGFJNA?oc=5","date":"2026-01-06","type":"regulatory","source":"TechStock²","summary":"Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny - TechStock²","headline":"Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxObmpOSnh6UF93ZktQZ2pRR1ZsRE11SXdBZkhyS2ozaEZuS1B0ZTB0YmU2ZnVCQ08yRkd6Umw3cDcteVZJTFhHeXZYRnZmSXVkaktFeHdSVkE2MUlGU0ctOGFKaXFidHZ2UTBWR09uU3dnRXlYaGljRlYxZ2VobFNfdjZxRS1RNDlmWVFvOXRmdGpDTXlxZ2RHeU55MA?oc=5","date":"2026-01-05","type":"pipeline","source":"Investor's Business Daily","summary":"Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. - Investor's Business Daily","headline":"Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQZDg1RXJRMDNNODM4aG5JMEpPUGN5Z1VCUnNWT0o1WUJaV3VveXMzeVNvU0Rhc2Vka1c3Y3VQVVd2clJwSHhXbTFFdFhiLWFRZVo3SXlma2N2LXc3NTZIc09ybzNsbEtSZDMtbF8wY1JYaEhNRVVOLTR4aklGaHJVdXMxSHlZQUllVmhUVVJtY0ZGMy1FR2hod2NCbUFFeGlrVnlUN3ZNd3hDSnJ6SWZyNlhzQ21JRXVPWkZvZUVzejYxMVRUSkxUY1lvV3JtQzg?oc=5","date":"2026-01-05","type":"trial","source":"Investing.com","summary":"Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results - Investing.com","headline":"Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNdm16dzhEUDRNOGNKWVU1RHZIMGZEZkhBQVc0Z0JPanAxN0RhenhYODlnaEpXd3JZMWFHdmpWT2VBOTYweDRFeENmUS11SUZtMzRmRG1TN1FwakpXWTZUOER6YjBQTktWam52OEZhd1d5UVFfNmJZUmRBSWdXNWY2eWJkMHh5ZWJBNHpYeFU1azNncFp5THBBZzg3VW1SUzZBcjJyZU45SmNUb0p1ZE5KLXVVLWt4cGtOU21wUlpB?oc=5","date":"2025-12-30","type":"regulatory","source":"TechStock²","summary":"Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus - TechStock²","headline":"Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNRVItQmpmS1BDa00xcE5EZ0VtTnJNU3pudVBlQ0VvLWJ1WEpIQWNCZndrZTdBN3I0OUg3MjctZWJaUHpWaXBMdk5kcndHZ18wUENRRDVzQVk5eWFjbUVkdWlOOEtKQlAyUnY1dkkxSk5VRF9JVFJnUVdDOWlscXFwRjIwQk9PMGF5dlNkLUZDSllRMzVJWUZKT3g2YjBWUkFtVXViYVRXQ2dXZTl1NHg2bTJndTBUcHJPR0xDMg?oc=5","date":"2025-11-12","type":"earnings","source":"Stock Titan","summary":"Zenas BioPharma (NASDAQ: ZBIO) Q3 2025; Royalty Pharma funding up to $300M - Stock Titan","headline":"Zenas BioPharma (NASDAQ: ZBIO) Q3 2025; Royalty Pharma funding up to $300M","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-08","type":"deal","source":"GlobeNewswire","summary":"Zenas BioPharma and InnoCare Pharma Announce License - GlobeNewswire","headline":"Zenas BioPharma and InnoCare Pharma Announce License","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQLWlsaHN1clBVTFUxNXRPZDhYckUtQUpyYlJuYVV4TVNNOHhNRFFHRGFZalB1blQwSkdLVVd1OVpkVmh5bkhlYTFBMkRCZHFxTEhsWndTQzRjbko3dkhCUkd6WFdRc0JMTVA5YVEzV1dJWEd5VW9QZ1RFUm4zZThlSHVFcENKZjM3a0djVUJObDc1cVNia0lOOWZFTnUzQVNDbWVHX2owZ0hQTEpPeHpsS2Vsdw?oc=5","date":"2025-10-08","type":"deal","source":"The Pharma Letter","summary":"Zenas inks license agreement with InnoCare for 3 autoimmune programs - The Pharma Letter","headline":"Zenas inks license agreement with InnoCare for 3 autoimmune programs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcHRlT1lSSWxFZVFQWFhFRlFqcnFteFBiSnJjc3ZLMl9XUWRFcERwNVZheDNFZnJUTzNGWnVnSlJmYVJaUWpNTi1OX2EtTElkT2ZVYzhDSEJpRmVFdmMySmlaU1lrZ296V1RqUVhYZlpxWW5SUUtaT0pubENwbUZVV2JtYWY0aEhnUGpSMmE5UXh6Sl9FY3BDQy1jVUJyeWJzYW40akdRMVJCOGxuRHM3QUE0N0ZrVHUyMlhuOTNfdUhzQmVURUR6d2JuVTluemxpRkxaSmxudjFjdw?oc=5","date":"2025-10-08","type":"deal","source":"Reuters","summary":"Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters","headline":"Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQX1l6UzZuUVk4UnVwWHVLRVJaTHh6eFRnZGhMd2s0ZlRNWHV6QmxfMXo1aGUyNUtqNHV6bGFQelFvdHltUUVEaGtPUDBzVjIwQ1RxZVNvYUpZMjJfV3F0OUZmMXpBSzNuUG1Ta0VmX3JjYlBLM0pGRmRfM3hyN0puZVVSNV82NmlKTW5ZR0QtQXQ4NW9zdHVsWDM3MkpJcVVkcUlBaXp1QUxidGpwWDlKU3pnZXVHaGhFbTEtWms4bUNFNWpZRUxIR0VzUldJMmx1eHFaT2ZSbnhxSlhEN2ZCUmRfSEwtWUprOENMNjZTZ2VGTmpWRmJXWVRUUUM?oc=5","date":"2025-09-02","type":"pipeline","source":"GlobeNewswire","summary":"Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - GlobeNewswire","headline":"Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-11","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Watching Zenas BioPharma's (NASDAQ:ZBIO) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Watching Zenas BioPharma's (NASDAQ:ZBIO) Cash Burn Situation","sentiment":"neutral"}],"patents":[{"drugName":"ZEN-271","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"ZEN-3694","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Sanofi"],"therapeuticFocus":["Autoimmune Diseases","Immunological Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":10000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":10000000,"period":"2025-12-31"},{"value":5000000,"period":"2024-12-31"},{"value":5000000,"period":"2024-12-31"},{"value":50000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":168063000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-377737000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":383640000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":167,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":20.86,"previousClose":22.48,"fiftyTwoWeekHigh":44.6,"fiftyTwoWeekLow":6.11,"fiftyTwoWeekRange":"6.11 - 44.6","fiftyDayAverage":23.06,"twoHundredDayAverage":23.29,"beta":0,"enterpriseValue":947615104,"forwardPE":-4.3,"priceToBook":4.69,"priceToSales":130.09,"enterpriseToRevenue":94.76,"enterpriseToEbitda":-4.48,"pegRatio":0,"ebitda":-211328992,"ebitdaMargin":0,"freeCashflow":-143104992,"operatingCashflow":-172332992,"totalDebt":1326000,"debtToEquity":0.5,"currentRatio":5.61,"returnOnAssets":-35.1,"returnOnEquity":-136.2,"analystRating":"","recommendationKey":"none","numberOfAnalysts":8,"targetMeanPrice":42,"targetHighPrice":55,"targetLowPrice":21,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":24.4,"institutionHeldPercent":70.6,"sharesOutstanding":62361260,"floatShares":35224976,"sharesShort":7709823,"shortRatio":13.04,"shortPercentOfFloat":13.4,"epsTrailing":-8.53,"epsForward":-4.88,"revenuePerShare":0.22,"bookValue":4.44,"officers":[{"age":68,"name":"Mr. Leon Oliver Moulder Jr., M.B.A.","title":"Founder, CEO & Chairman"},{"age":53,"name":"Mr. Joseph L. Farmer","title":"COO & President"},{"age":66,"name":"Dr. Lisa  von Moltke M.D.","title":"Head of Research & Development and Chief Medical Officer"},{"age":53,"name":"Ms. Jennifer A. Fox","title":"Chief Business Officer & CFO"},{"age":null,"name":"Dr. Heinrich  Schlieker Ph.D.","title":"Chief Technical Officer"},{"age":null,"name":"Dr. Haley  Laken Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Caroline  Chevalier","title":"Chief Administrative Officer"},{"age":56,"name":"Mr. Jeffrey  Held","title":"Chief Legal Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://zenasbio.com","phone":"857 271 2954"}}